Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HX008 plus bevacizumab or lenvatinib as first-line treatment for advanced hepatocellular carcinoma
CTR20202078Phase 2Completed
- Sponsor
- Taizhou Hanzhong Biomedical
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab, bevacizumab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Taizhou Hanzhong Biomedical. Started Jan 2021; status: completed.
02
Drugs
pucotenlimabbevacizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20202078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202078.